I.V. Nicotine

Phase 1Small molecule

YYale University

I.V. Nicotine is one of 18 small molecule programs targeting Metabolism. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MetabolismActive, not recruiting

MetabolismPhase 1

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Metabolism

#DrugCompanyPhaseTrials

Ethanol

Roche

Phase 3

1 2

Cymbalta

Jazz Pharmaceuticals

Phase 1

2 3

Bayer Aspirin

Bayer

Phase 1

1 4

Rapamycin

MMaastricht Radiation Oncology

Phase 2

1 5

Tasmar

BBausch Health Americas, Inc.

Phase 1

1 6

Atropen

FFresenius Kabi Taiwan Ltd.

Phase 1

1 7

Exendin-(9-39)

EEiger BioPharmaceuticals

Phase 1

3 8

Obicetrapib

NNewAmsterdam Pharma

Phase 1

1 9

Quemliclustat

Arcus Biosciences

Phase 1

1 10

Dilantin

VViatris Specialty LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Metabolism

NCT03442413

Clinical

Trials by Indication[1]

Smokers2 trials

Galantamine Effects on Nicotine Responses in Smokers

Completed·YYale University·Phase 1·NCT01417429·12 enrolled

Effects of Flavors on Nicotine Reinforcement in Smokers

Completed·YYale University·Phase 1·NCT03243630·26 enrolled

Metabolism1 trial

Nicotinic Hepatic Metabolism on Neuroreceptor Substrates of Nicotine Addiction

Active, not recruiting·UUniversity of Pennsylvania·Phase 1·NCT03442413·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for I.V. Nicotine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — I.V. Nicotine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for I.V. Nicotine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yale University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: YYale University

I.V. Nicotine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Smokers2 trials

Metabolism1 trial

References

Drug Info

Quick Facts

Related News